Brief: Cstone Pharmaceuticals Announced Acceptance Of New Drug Application For Pralsetinib
17/02/2022 24:49
Feb 17 (Reuters) - CStone Pharmaceuticals 2616.HK :
* CSTONE PHARMACEUTICALS ANNOUNCED ACCEPTANCE OF NEW DRUG
APPLICATION FOR PRALSETINIB
Source text for Eikon: ID:
Further company coverage: 2616.HK
(Reuters.briefs@thomsonreuters.com)
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026